In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $1.00 down -6.54% from its previous closing price of $1.07. In other words, the price has decreased by -$6.54 from its previous closing price. On the day, 3.84 million shares were traded.
Ratios:
For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.71.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.99 while its Price-to-Book (P/B) ratio in mrq is 5.33.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is -32.97%, while the 200-Day Moving Average is calculated to be -10.96%.
Shares Statistics:
A total of 208.62M shares are outstanding, with a floating share count of 200.01M. Insiders hold about 4.14% of the company’s shares, while institutions hold 29.74% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $11.7M this quarter.It ranges from a high estimate of $20M to a low estimate of $200k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $2.04MFor the next quarter, 7 analysts are estimating revenue of $30.67M. There is a high estimate of $70M for the next quarter, whereas the lowest estimate is $10M.
A total of 6 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $71M, while the lowest revenue estimate was $50.4M, resulting in an average revenue estimate of $62.32M. In the same quarter a year ago, actual revenue was $176.23MBased on 7 analysts’ estimates, the company’s revenue will be $73.52M in the next fiscal year. The high estimate is $200M and the low estimate is $20.84M.
